---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-124836"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-11-10T13:30:22+00:00"
generated_at: "2026-11-10T13:35:04.971852+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN; up to $7.1M in payments plus royalties

## Summary
- Celairis gets exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand and ASEAN markets.
- Ocugen receives an upfront fee plus development/milestone payments up to $7.1M, including $6.1M tied to the upfront payment and Phase 3 liMeliGhT top-line data expected in Q1 2027.
- Separate $1.0M milestone payable on Therapeutic Goods Administration approval in Australia; Ocugen also gets a high single-digit percentage royalty on net sales and 50% of gross profits.
- Ocugen retains sole manufacturing rights and the parties target a supply agreement within 90 days; territory covers an estimated 725 million people and can expand by mutual agreement.
- Ocugen calls it the third strategic regional partnership for OCU400; U.S. BLA and EU MAA filings are planned after the Q1 2027 topline readout.

## SEC filing metadata
- accession: 0001104659-26-124836
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-11-10T13:30:22+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/0001104659-26-124836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-124836
- JSON: https://secwatch.observer/filing/0001104659-26-124836.json
- Plain text: https://secwatch.observer/filing/0001104659-26-124836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.